Oligonucleotides


  • CMIC Small Molecule services


Since 2012, we have supported hundreds of studies for oligonucleotide-based drugs, including: qualification, full method validation and GLP sample analysis studies for oligonucleotide-based drugs, in tissue and plasma for preclinical and clinical studies.

What Sets Us Apart?
• Partnered with recognized global leaders in RNA-targeted discoveries
•Nearly 100 individual compounds successfully validated since 2012
•Vast experience with chemically modified oligonucleotides including GalNAc conjugate, cholesterol conjugate, thymidylic acid and phosphate


Experience

Decoy
Antisense
siRNA
Aptamer

Platforms

HPLC-UV, Hybridization,
LC-MS/MS, HPLC-FD,
LC-HRMS, qPCR,
ECL

Capabilities

Method transfer, development & qualification, Full validation, Quantitative bioanalysis, Metabolite ID & confirmation

Biomatrix

Plasma/Serum, Urine, CSF, Muscle, Liver, Kidney, Lung, Brain, Heart, Tumor Tissue, PBMC, Ocular


Drug Development Stages

Bioanalysis for non-clinical and clinical stages of drug development


Method
Development
Method
Transfer
Method
Qualification
Cross
Validation
Sample
Analysis

Request More Information on CMIC Oligonucleotide Bioanalysis Services